search
Back to results

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Omarigliptin
Placebo to omarigliptin
Pioglitazone
Metformin
Placebo to metformin
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.

The participant:

  • Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age;
  • Has a body mass index (BMI) > 20 kg/m^2 and < 43 kg/m^2; for Japan: BMI >18 kg/m^2 and <43 kg/m^2;
  • Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks) or is on oral AHA therapy but has inadequate glycemic control;
  • Is a male, or a female who is highly unlikely to conceive.

Exclusion Criteria:

If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.

The participant:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis;
  • Is on a weight loss program or has started a weight loss medication within the prior 8 weeks;
  • Has required insulin therapy within 14 weeks prior to signing informed consent;
  • Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease;
  • Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease;
  • Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder;
  • Has a history of malignancy or clinically important hematological disorder

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm 7

    Arm 8

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Experimental

    Active Comparator

    Arm Label

    Omarigliptin 0.25 mg (Base)

    Omarigliptin 1 mg (Base)

    Omarigliptin 3 mg (Base)

    Omarigliptin 10 mg (Base)

    Omarigliptin 25 mg (Base)

    Placebo (Base)

    Pooled omarigliptin (Extension)

    Placebo/Metformin

    Arm Description

    Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)

    Omarigliptin 1 mg administered once weekly for 12 weeks (Base)

    Omarigliptin 3 mg administered once weekly for 12 weeks (Base)

    Omarigliptin 10 mg administered once weekly for 12 weeks (Base)

    Omarigliptin 25 mg administered once weekly for 12 weeks (Base)

    Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)

    Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).

    Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.

    Outcomes

    Primary Outcome Measures

    Change From Baseline in Plasma A1C Levels at Week 12
    A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Percentage of Participants Who Experienced at Least One Adverse Event During the Base Period
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During the 12-week Base Period
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Percentage of Participants Who Experienced at Least One Adverse Event During the 66-week Extension Period
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.

    Secondary Outcome Measures

    Change From Baseline in 2 Hour-post-meal Glucose (2h-PMG) Levels at Week 12
    Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Change From Baseline in Fasting Plasma Glucose (FPG) Levels at Week 12
    Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Mean Plasma A1C Level at Baseline of the Extension Period
    A1C levels were measured as a percent at baseline (Week 0) for participants who entered the extension period.
    Change From Baseline in Plasma A1C Levels at Week 78
    A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 78 level.
    Mean 2h-PMG Level at Baseline of the Extension Period
    Plasma 2h-PMG levels were measured at baseline (Week 0) for participants who entered the extension period.
    Change From Baseline in 2h-PMG at Week 78
    Change from baseline was calculated by subtracting the baseline level from the Week 78 level.
    Mean FPG Level at Baseline of the Extension Period
    Plasma FPG levels were measured at baseline (Week 0) for particiapnts who entered the extension period.
    Change From Baseline in FPG Levels at Week 78
    Change from baseline was calculated by subtracting the baseline level from the Week 78 level.

    Full Information

    First Posted
    October 6, 2010
    Last Updated
    August 8, 2018
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01217073
    Brief Title
    A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
    Official Title
    A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    October 8, 2010 (Actual)
    Primary Completion Date
    January 3, 2012 (Actual)
    Study Completion Date
    April 1, 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks of treatment. The study will evaluate 5 different doses of omarigliptin to identify which dose is the most effective in the treatment of type 2 diabetes.
    Detailed Description
    MK-3102-006-Ext 1 added a 66-week extension to the base study (MK-3102 P006) to assess the long-term safety and tolerability of omarigliptin. To be eligible for the extension, participants must complete the double-blind base study, must have had at least a 75% compliance with study drug during the base study and can not meet any of the criteria for discontinuation. Participants randomized to placebo in the base study will be switched in a blinded manner to pioglitazone 30 mg once daily, in the extension study prior to implementation of amendment P006-13. Once amendment P006-13 has been IRB/IEC approved and blinded metformin drug supply is available at the site, participants will be switched from pioglitazone to metformin, starting at 500 mg once daily and titrated up to 1000 mg twice daily. Participants with a contraindication to metformin will be discontinued from the study. Participants randomized to 0.25 mg, 1 mg, 3 mg, and 10 mg of omarigliptin in the base study will be switched to omarigliptin 25 mg; those randomized to 25 mg of omarigliptin in the base study will continue on the same dose in the extension study. After the clinical dose of omarigliptin selected for further development has been identified based upon the results of the base study, all participants randomized to omarigliptin will be switched to the identified clinical dose.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    685 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Omarigliptin 0.25 mg (Base)
    Arm Type
    Experimental
    Arm Description
    Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
    Arm Title
    Omarigliptin 1 mg (Base)
    Arm Type
    Experimental
    Arm Description
    Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
    Arm Title
    Omarigliptin 3 mg (Base)
    Arm Type
    Experimental
    Arm Description
    Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
    Arm Title
    Omarigliptin 10 mg (Base)
    Arm Type
    Experimental
    Arm Description
    Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
    Arm Title
    Omarigliptin 25 mg (Base)
    Arm Type
    Experimental
    Arm Description
    Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
    Arm Title
    Placebo (Base)
    Arm Type
    Placebo Comparator
    Arm Description
    Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
    Arm Title
    Pooled omarigliptin (Extension)
    Arm Type
    Experimental
    Arm Description
    Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
    Arm Title
    Placebo/Metformin
    Arm Type
    Active Comparator
    Arm Description
    Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
    Intervention Type
    Drug
    Intervention Name(s)
    Omarigliptin
    Intervention Description
    Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to omarigliptin
    Intervention Description
    Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
    Intervention Type
    Drug
    Intervention Name(s)
    Pioglitazone
    Intervention Description
    Pioglitazone 15 mg oral tablet or capsule administered once daily
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin
    Intervention Description
    Metformin 500 mg oral tablet administered once or twice daily
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to metformin
    Intervention Description
    Matching placebo to metformin oral tablet administered once daily
    Primary Outcome Measure Information:
    Title
    Change From Baseline in Plasma A1C Levels at Week 12
    Description
    A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Time Frame
    Baseline (Week 0) and Week 12
    Title
    Percentage of Participants Who Experienced at Least One Adverse Event During the Base Period
    Description
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Time Frame
    Up to 16 weeks (including 28 days following the last dose of study drug)
    Title
    Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event During the 12-week Base Period
    Description
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Time Frame
    Up to 12 weeks
    Title
    Percentage of Participants Who Experienced at Least One Adverse Event During the 66-week Extension Period
    Description
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Time Frame
    Up to 70 Weeks (Weeks 12 to 78 plus 4-week follow-up period)
    Title
    Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event During the 66-week Extension Period
    Description
    An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse event. Data presented below excludes data after the initiation of glycemic rescue.
    Time Frame
    Up to 66 weeks (Weeks 12 to 78)
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in 2 Hour-post-meal Glucose (2h-PMG) Levels at Week 12
    Description
    Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Time Frame
    Baseline (Week 0) and Week 12
    Title
    Change From Baseline in Fasting Plasma Glucose (FPG) Levels at Week 12
    Description
    Change from baseline was calculated by subtracting the baseline level from the Week 12 level.
    Time Frame
    Baseline (Week 0) and Week 12
    Title
    Mean Plasma A1C Level at Baseline of the Extension Period
    Description
    A1C levels were measured as a percent at baseline (Week 0) for participants who entered the extension period.
    Time Frame
    Baseline (Week 0)
    Title
    Change From Baseline in Plasma A1C Levels at Week 78
    Description
    A1C levels were measured as a percent. Change from baseline was calculated by subtracting the baseline level from the Week 78 level.
    Time Frame
    Baseline (Week 0) and Week 78
    Title
    Mean 2h-PMG Level at Baseline of the Extension Period
    Description
    Plasma 2h-PMG levels were measured at baseline (Week 0) for participants who entered the extension period.
    Time Frame
    Baseline (Week 0)
    Title
    Change From Baseline in 2h-PMG at Week 78
    Description
    Change from baseline was calculated by subtracting the baseline level from the Week 78 level.
    Time Frame
    Baseline (Week 0) and Week 78
    Title
    Mean FPG Level at Baseline of the Extension Period
    Description
    Plasma FPG levels were measured at baseline (Week 0) for particiapnts who entered the extension period.
    Time Frame
    Baseline (Week 0)
    Title
    Change From Baseline in FPG Levels at Week 78
    Description
    Change from baseline was calculated by subtracting the baseline level from the Week 78 level.
    Time Frame
    Baseline (Week 0) and Week 78

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation. The participant: Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to 70 years of age; Has a body mass index (BMI) > 20 kg/m^2 and < 43 kg/m^2; for Japan: BMI >18 kg/m^2 and <43 kg/m^2; Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks) or is on oral AHA therapy but has inadequate glycemic control; Is a male, or a female who is highly unlikely to conceive. Exclusion Criteria: If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation. The participant: Has a history of type 1 diabetes mellitus or a history of ketoacidosis; Is on a weight loss program or has started a weight loss medication within the prior 8 weeks; Has required insulin therapy within 14 weeks prior to signing informed consent; Has a medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic gallbladder disease; Has congestive heart failure or has new or worsening signs or symptoms of coronary heart disease; Had any of the following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder; Has a history of malignancy or clinically important hematological disorder
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Citations:
    PubMed Identifier
    26310692
    Citation
    Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes. Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26.
    Results Reference
    result
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/study.html?id=3102-006&kw=3102-006&tab=access

    Learn more about this trial

    A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

    We'll reach out to this number within 24 hrs